Physician profile
Matthew E Esperon
NPI 1568442911
$13,601.49
in general payments reported to CMS, 2019-2025
29 companies · $6,797 in 2025
The $6,797 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $1,475 · 2021: $615 · 2022: $1,166 · 2023: $1,499 · 2024: $1,519 · 2025: $6,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,759 · Education: $35.68 · Entertainment: $20.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,759.46 |
| Education | $35.68 |
| Entertainment | $20.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $5,742.98 | 2022-2025 | Optilight, M22 |
| Coopervision INC. | $2,241.58 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Paragon Crt |
| Alcon Vision LLC | $1,251.37 | 2019-2025 | Dailies Total1, Total30, Precision7 |
| Sun Pharmaceutical Industries INC. | $1,013.64 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $364.45 | 2022-2025 | Miebo, Xiidra, Infuse |
| Biotissue Holdings INC. | $363.04 | 2022-2024 | |
| Oyster Point Pharma, INC. | $281.20 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $258.80 | 2024-2025 | Xdemvy |
| Rxsight INC | $235.45 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Visioneering Technologies, INC. | $198.14 | 2019-2025 | |
| Lkc Technologies, INC. | $182.48 | 2023-2024 | |
| Glaukos Corporation | $170.48 | 2021 | |
| Sight Sciences, INC. | $164.71 | 2023 | Tearcare System |
| Harrow Eye, LLC | $155.81 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $151.57 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $107.55 | 2020-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Topcon Healthcare, INC. | $106.66 | 2024 | |
| Abb Con-Cise Optical Group LLC | $104.51 | 2023 | Contact Lens, Spectacle Lenses |
| Maculogix, INC. | $95.44 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $90.20 | 2020-2022 | |
| Allergan, INC. | $76.61 | 2020-2021 | |
| Dompe US, INC. | $50.69 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $47.05 | 2020-2022 | |
| Shire North American Group INC | $40.47 | 2019 | |
| Kala Pharmaceuticals, INC. | $40.47 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.96 | 2022 | |
| Abbvie INC. | $17.17 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $15.02 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Esperon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.